The fixed dose combinations in the categories of analgesics and orthopaedics lead the list of FDCs to be withdrawn from the market following the agreement between the industry and the DCGI over the vexed issue, according to the minutes of the first meeting released recently.
The largest number of number of combinations to be banned or discontinued from the market had aspirin as a component, followed by paracetamol, according to the minutes of the meeting held on July 14, but belatedly released in the second meeting held on October 1.
The details of the Banned and absurd FDC's can be read here.
No comments:
Post a Comment